#United States #Vascarta #Summit #Vasceptor #Dr. Loesberg

Vascarta Welcomes Dr. Janet Loesberg to Leadership Team

Vascarta Inc., a forward-thinking clinical-stage pharmaceutical company, has recently announced a significant addition to its leadership team with the appointment of Dr. Janet Loesberg, PharmD, as its Fractional Chief Strategy Officer. This strategic move, effective immediately, is set to bolster the company's corporate strategy, portfolio management, and investor relations activities in the pharmaceutical landscape.

With extensive experience in the pharmaceutical industry, Dr. Loesberg brings a wealth of knowledge and leadership skills to Vascarta. She has held key roles in global medical affairs and research and development at major pharmaceutical companies including Blueprint Medicines, Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), Bristol-Myers Squibb, and Pfizer. Most notably, as the Senior Vice President at Blueprint Medicines, Dr. Loesberg played a crucial role in the successful launch of Ayvakit™ (avapritinib), a groundbreaking treatment for indolent systemic mastocytosis, a rare hematologic disorder.

The expertise that Dr. Loesberg offers is particularly valuable to Vascarta as the company aims to develop Vasceptor® (VAS-101) for sickle cell disease, an area that Dr. Loesberg is familiar with, courtesy of her extensive experience with the hematological community. Dr. Richard Prince, Vascarta's Chairman and CEO, expressed enthusiasm about her arrival: “We are thrilled to welcome Janet to Vascarta. Her deep industry expertise and experience in business transformation are invaluable as we focus on our development efforts.” This strong emphasis on developing Vasceptor® for sickle cell disease and osteoarthritis highlights the company’s commitment to addressing significant medical needs within these communities.

In her new role, Dr. Loesberg is expected to lead corporate strategy development and will be directly involved in portfolio and pipeline management, strategic communication, and fundraising initiatives. Her insights into the healthcare market will guide Vascarta as it navigates the complex processes associated with bringing new medical treatments to patients in need.

Dr. Loesberg shared her excitement about joining the Vascarta team, stating, “I am excited to join Vascarta and its promise to bring relief to patients suffering from chronic inflammatory diseases. I am focused on accelerating the development of Vasceptor® and preparing for its launch.” She emphasized the importance of collaboration with the existing talented team at Vascarta in turning their vision into reality.

As Vascarta Inc. continues to make strides in efficient transdermal and transmucosal delivery of pharmaceuticals targeting inflammatory conditions, the addition of Dr. Loesberg sets a promising tone for the company’s future operations. The firm is currently focused on transitioning their innovative treatments to the market, aiming to provide significant relief for patients affected by sickle cell disease and osteoarthritis.

As the launch of Vasceptor® approaches, both the team at Vascarta and industry observers alike will be keenly watching how Dr. Loesberg's leadership impacts the company’s trajectory. Her proven track record in the pharmaceutical industry, combined with her strategic vision, is expected to greatly contribute to Vascarta’s ongoing success in the pharmaceutical landscape. This leadership decision not only illustrates Vascarta's commitment to growth but also a proactive approach to addressing compelling health challenges that patients face today.